Humacyte (NASDAQ:HUMA) Receives Buy Rating from D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Humacyte (NASDAQ:HUMA) in a research report sent to investors on Friday,Benzinga reports. The brokerage currently has a $25.00 price target on the stock.

HUMA has been the topic of several other research reports. Wall Street Zen lowered shares of Humacyte from a “hold” rating to a “sell” rating in a research report on Sunday, December 21st. Benchmark lowered their target price on shares of Humacyte from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, January 21st. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price target on shares of Humacyte in a report on Monday, December 1st. BTIG Research reduced their price target on Humacyte from $6.00 to $3.00 and set a “buy” rating for the company in a research report on Friday. Finally, UBS Group reiterated a “buy” rating on shares of Humacyte in a research note on Monday, December 1st. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Humacyte has a consensus rating of “Moderate Buy” and an average price target of $7.71.

Humacyte Trading Down 13.2%

Shares of Humacyte stock opened at $0.68 on Friday. Humacyte has a 1 year low of $0.67 and a 1 year high of $2.93. The stock has a fifty day moving average price of $1.04 and a 200-day moving average price of $1.28. The company has a debt-to-equity ratio of 2.97, a current ratio of 1.62 and a quick ratio of 0.90. The firm has a market cap of $126.52 million, a PE ratio of -2.94 and a beta of 1.89.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings data on Friday, March 27th. The company reported ($0.13) EPS for the quarter, hitting the consensus estimate of ($0.13). The company had revenue of $0.47 million during the quarter, compared to the consensus estimate of $1.35 million. Equities research analysts anticipate that Humacyte will post -1.27 EPS for the current year.

Hedge Funds Weigh In On Humacyte

A number of institutional investors have recently added to or reduced their stakes in HUMA. R Squared Ltd purchased a new stake in shares of Humacyte in the 4th quarter valued at about $25,000. Atom Investors LP bought a new stake in Humacyte during the fourth quarter valued at approximately $25,000. Truist Financial Corp purchased a new position in Humacyte in the 3rd quarter worth approximately $28,000. Prudential Financial Inc. purchased a new position in Humacyte in the 2nd quarter worth approximately $28,000. Finally, Financial Advisors Network Inc. bought a new position in shares of Humacyte in the 2nd quarter worth $28,000. 44.71% of the stock is currently owned by institutional investors.

Humacyte News Roundup

Here are the key news stories impacting Humacyte this week:

• Positive Sentiment: D. Boral Capital reaffirmed a “buy” rating and set an outsized $25.00 price target, signaling strong upside expectations from that firm. Benzinga
• Positive Sentiment: Humacyte named Rick McElheny SVP of Business Development to expand collaborations and commercialization efforts—management hire aimed at accelerating partnerships that could drive future revenue. GlobeNewswire: Appointment
• Neutral Sentiment: Full earnings call transcript is available for investors wanting management commentary and Q&A that could clarify outlook and commercial plans. Earnings Call Transcript
• Negative Sentiment: Q4 results: GAAP loss of ($0.13) per share met consensus, but revenue came in at roughly $0.47–0.5M versus analyst expectations near $1.35M (and full‑year sales only $2.0M). The revenue shortfall and low near-term sales reduce near-term visibility and likely pressured the stock. MarketBeat: Earnings Press Release Zacks
• Negative Sentiment: BTIG reduced its price target from $6.00 to $3.00 (still a “buy”), signaling a more cautious near-term outlook from another sell-side firm and lowering consensus upside. Benzinga

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.